Background
==========

Worldwide, hypertension contributes to more than 10 million deaths and it affects one-third of the adult population per year \[[@B1]\]. It was predicted that the incidence of hypertension among adults in 2025 will reach 1.56 billion and contribute to approximately 54% of stroke and 47% of ischemic heart disease. Furthermore, it is a major risk factor for cardiovascular disease \[[@B2]\]. Several factors, including genetic, environmental, and demographic factors, play a major role in the development of hypertension. However, it is believed that 30% to 60% of the variability in blood pressure (BP) is inherited \[[@B1]\].

Many genome-wide association studies (GWAS) have been conducted to identify single-nucleotide polymorphism (SNPs) that are significantly associated with systolic blood pressure (SBP), diastolic blood pressure (DBP), and/or hypertension.

Meta-analysis findings of the Global BPgen (Global Blood Pressure Genetics) consortium (n = 34,433) and CHARGE (The Cohorts for Heart and Aging Research in Genome Epidemiology) consortium (n = 29,136) based on populations of European ancestry identified 4 loci significantly associated with SBP (ATP2B1, CYP17A1, PLEKHA7, SH2B3), 6 associated with DBP (ATP2B1, CACNB2, CSK-ULK3, SH2B3, TBX3-TBX5, ULK4), and 1 associated with hypertension (ATP2B1) \[[@B1]\]. However, a genome-wide association study by Adeyemo et al \[[@B3]\] based on a population of African Americans (n = 1017) identified significant loci for SBP in or near the genes *PMS1, SLC24A4, YWHA7, IPO7*, and *CACANA1H*, while no significant loci were discovered to be associated with DBP or hypertension.

Unlike single-gene analysis, pathway-based approaches consider multiple genes that are related together within gene sets/pathways; these pathways are predefined gene sets from biological databases. The aim of pathway-based approaches is to assess the significance of these sets/pathways by evaluating the enrichment of genes within a pathway at the top of a list of ranked genes \[[@B4]-[@B6]\]. Pathway-based analysis was originally applied to gene expression data; however, it has also been applied to GWAS data \[[@B4]\]. In this paper, we use a pathway-based approach based on Gene Set Enrichment Analysis (GSEA) \[[@B4]\]. We consider both rare and common variants and incorporate other covariates, including age, gender, use of antihypertensive medications, and smoking status. Our main focus is to test the effects of both rare and common variants on SBP, DBP, the difference between them (SBP-DBP), and mean arterial pressure (defined as MAP = \[⅔ DBP\] + \[⅓ SBP\]) by applying GSEA.

Methods
=======

Phenotype and covariate data description
----------------------------------------

This data set was provided by the organizers of the Genetic Analysis Workshop 18 (GAW18). From this data set, we considered the 157 unrelated individuals with their phenotypes. Phenotypes were taken at 4 time points and included systolic and DBP measurements and hypertension. The following covariates were also provided: age, smoking status, antihypertensive medications usage, and gender. In our analysis, we used the baseline data; among the 157 unrelated individuals we had 129 individuals who had been genotyped. Table [1](#T1){ref-type="table"} summarizes the data.

###### 

Descriptive statistics for phenotypes and covariates at baseline for 129 unrelated individuals

  Variable                    Summary measure\*
  --------------------------- -------------------
  SBP                         128.4 ± 21.8
  DBP                         71.8 ± 9.2
  MAP                         90.7 ± 11.6
  SBP-DBP                     56.6 ± 19
  Hypertension (Yes, No)      129 (29.5)
  Age                         52.9 ± 15.6
  Sex (Female)                129 (60.5)
  Medications use (Yes, No)   129 (20.2)
  Smoking status (Yes, No)    129 (24.8)

\*Mean ± SD for continuous variables; n(%) for categorical variables.

Genotype data description
-------------------------

Genotype data were provided only for odd-numbered autosomal chromosomes. In this paper, we focus on variants on chromosome 3 (as suggested by the GAW18 organizers to allow comparisons of findings with other GAW18 contributions).

Pathway-based analysis
----------------------

We considered 4 phenotypes of interest SBP, DBP, SBP-DBP, and MAP and performed pathway-based analysis. We followed the following steps \[[@B4],[@B5]\]:

### Step 1: Mapping SNPs to genes

Among the 1,215,296 SNPs on chromosome three, 523,147 SNPs were mapped to 1224 known genes using NBCI2R.

### Step 2: Obtaining test statistics for genes

We considered both rare and common variants and other covariates (age, smoking status, medications use, and gender) to assign a test statistic for each gene. VW-TOW (variable weight test for testing the effect of an optimally weighted combination of variants) \[[@B8]\] was used to construct test statistics and their *p*values. Assume that we have *n*individuals who have been genotyped at *M*variants and is the trait of interest for the *i*^th^individual. Each individual has a genotypic score ^T^where {0,1,2} denotes the number of copies of the minor allele for the *m*^th^variant of the *i*^th^individual. We used a minor allele frequency (MAF) threshold of less than 1% to define rare variants. To test the effect of the optimally weighted combination (TOW) of variants $x_{i}^{0} = \sum_{m = 1}^{M}w_{m}^{0}x_{im}$, we used the statistic:

$$T_{T} = \sum\limits_{i = 1}^{n}\left( {y_{i} - \overset{-}{y}} \right)\left( {x_{i}^{0} - {\overline{x}}^{0}} \right)$$

where $w_{m}^{0} = \sum_{i = 1}^{n}\left( {y_{i} - \overset{-}{y}} \right)\left( {x_{im} - {\overline{x}}_{m}} \right)/\sum_{i = 1}^{n}\left( {x_{im} - {\overline{x}}_{m}} \right)^{2}$ are the optimal weights.

To test the effect of both rare and common variants, we applied TOW to each of them separately; $T_{r}$ and $T_{c}$ denote these statistics, respectively. Then we used the test statistic of VW-TOW:

$$T_{VW\text{\_}T} = \underset{0 \leq \lambda \leq 1}{\text{min}}p_{\lambda}$$

where $p_{\lambda}$ is the *p*value of the test $T_{\lambda}$ and $T_{\lambda} = \lambda\frac{T_{r}}{\sqrt{var\left( T_{r} \right)}} + \left( {1 - \lambda} \right)\frac{T_{c}}{\sqrt{var\left( T_{c} \right)}}$. To evaluate the *p*value of $T_{VW\text{\_}T}$, we used the permutation test.

We incorporated the other covariates $\left( {z_{i1},\ldots,z_{ip}} \right)$^T^for each individual *i*, by adjusting $y_{i}$ and $x_{im}$ using linear regression:

$$y_{i} = \alpha_{0} + \alpha_{1}z_{i1} + \ldots + \alpha_{p}z_{ip} + \varepsilon_{i}\text{~and}$$

$$x_{im} = \alpha_{0m} + \alpha_{1m}z_{i1} + \ldots + \alpha_{pm}z_{ip} + \tau_{im}$$

And by using the residuals ${\overset{\sim}{y}}_{i}$ and ${\overset{\sim}{x}}_{im}$, the following TOW and VW-TOW were used:

$$T_{TOW} = T_{T|y_{i} = {\overset{\sim}{y}}_{i},x_{im} = {\overset{\sim}{x}}_{im}}\text{~and}$$

$$T_{VW\text{\_}TOW} = T_{VW - T|y_{i} = {\overset{\sim}{y}}_{i},x_{im} = {\overset{\sim}{x}}_{im}}$$

### Step 3: Pathway analysis

We ranked all the genes (N), that had *p*values and test statistics, based on their statistical significance from the smallest to the largest *p*values. From step 2, we had (N = 1187) genes for SBP and DBP and (N = 1188) genes for SBP-DBP and MAP. Using the GSEA method \[[@B6]\], we evaluated the significance of predefined gene sets/pathways obtained from online pathway databases (The Molecular Signatures Database) \[[@B9]\]. We used the c2 curated gene sets (v3.1), which are compiled from online pathway databases, publications in PubMed, and knowledge of domain experts \[[@B9]\], which consisted of 4850 gene sets, but we only considered 3638 sets that had at least 1 gene from chromosome 3 and at least 10 genes in total. Of the 3638 pathways, 69.1% have between 1 and 5 genes on chromosome 3, while 24.1% of the pathways have between 6 and 20 genes and 6.8% have between 21 and 140 genes on the same chromosome. Then we calculated the enrichment score (ES) for each set/pathway using a weighted Kolmogorov-Smirnov-like running-sum statistic. This statistic describes the overrepresentation of the genes within the set at the top of the ranked genes. We then adjusted for different sizes of genes using 1000 gene-based permutations (π) and calculated the normalized enrichment score (NES) for each set (*S*).

$$\text{NES}\left( S \right) = \frac{Actual\left( {ES\left( S \right)} \right)}{mean\left( {ES\left( {S,\pi} \right)} \right)}$$

To estimate the significance level of NES for each set/pathway, we used the gene-based permutation approach to obtain the empirical *p*values of the NES. We used 1000 gene-set permutations and then we considered the set/pathway to be significantly enriched if its false discovery rate (FDR) *q*value is less than 0.05. We implemented the analysis using the GSEApreranked tool included in the GSEA software \[[@B6],[@B7]\].

Results
=======

Considering common and rare variants from chromosome 3 with other covariates, and applying GSEA to our data, we ranked the top 10 gene sets/pathways based on their FDR *q*values for each phenotype. These ranked genes are listed in Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, and [5](#T5){ref-type="table"} for MAP, (SBP-DBP), SBP, and DBP phenotypes, respectively. We found that no gene sets were enriched when we considered SBP or DBP. However, we were able to identify 1 significant enriched gene pathway from c2 curated gene sets (Table [2](#T2){ref-type="table"}) with MAP. Interestingly, the same pathway was declared to be significantly enriched with the difference between SBP and DBP phenotype (Table [3](#T3){ref-type="table"}). We identified the same gene pathway (Koyama_Sema3B_Targets_DN) in both phenotypes, and this pathway had been shown to be related to different kinds of cancer \[[@B10],[@B11]\]. In this pathway, 12 of 18 genes on chromosome 3 contributed to the enrichment score and the most interesting gene in this pathway is CD47. Several articles \[[@B12],[@B13]\] reported that this gene regulates BP.

###### 

The top 10 gene sets/pathways from c2 curated gene sets ranked by FDR *q*values for MAP

  Pathway name                                  No. genes\*   ES      NES     FDR *q*value
  --------------------------------------------- ------------- ------- ------- --------------
  KOYAMA_SEMA3B_TARGETS_DN                      18            0.611   2.226   0.040
                                                                              
  HUANG_GATA2_TARGETS_UP                        11            0.559   1.769   0.903
                                                                              
  ONO_FOXP3_TARGETS_DN                          5             0.724   1.757   0.929
                                                                              
  BENPORATH_ES_2                                4             0.859   1.938   0.967
                                                                              
  CARDOSO_RESPONSE_TO_GAMMA_RADIATION_AND_3AB   3             0.865   1.770   0.980
                                                                              
  ZHANG_TLX_TARGETS_60HR_UP                     22            0.423   1.625   0.981
                                                                              
  LAIHO_COLORECTAL_CANCER_SERRATED_DN           1             0.891   1.202   0.992
                                                                              
  PID_INTEGRIN2_PATHWAY                         1             0.915   1.203   0.992
                                                                              
  LIU_TARGETS_OF_VMYB_VS_CMYB_DN                5             0.501   1.203   0.992
                                                                              
  LIM_MAMMARY_STEM_CELL_DN                      21            0.317   1.203   0.992

\*Number of genes on chromosome 3.

###### 

The top 10 gene sets/pathways from c2 curated gene sets ranked by FDR q-values for the difference between SBP and DBP

  Pathway name                                                        No. genes\*   ES      NES     FDR *q*value
  ------------------------------------------------------------------- ------------- ------- ------- --------------
  KOYAMA_SEMA3B_TARGETS_DN                                            18            0.614   2.227   0.042
  ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_UP                                4             0.830   1.867   0.822
  TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP            7             0.691   1.888   0.823
  BREDEMEYER_RAG_SIGNALING_NOT_VIA_ATM_DN                             4             0.811   1.844   0.871
  LI_INDUCED_T\_TO_NATURAL_KILLER_DN                                  7             0.693   1.907   0.892
  BENPORATH_ES_2                                                      4             0.858   1.941   0.917
  TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINED_IN_GRANULOCYTE_UP   3             0.869   1.762   0.958
  CHANG_CORE_SERUM_RESPONSE_DN                                        21            0.290   1.091   0.976
  WONG_ENDMETRIUM_CANCER_UP                                           2             0.625   1.082   0.976
  NOUZOVA_TRETINOIN_AND_H4_ACETYLATION                                18            0.299   1.090   0.976

\*Number of genes on chromosome 3.

###### 

The top 10 gene sets/pathways from c2 curated gene sets ranked by FDR *q*values for SBP

  Pathway name                                   No. genes\*   ES      NES     FDR *q*value
  ---------------------------------------------- ------------- ------- ------- --------------
  GOTTWEIN_TARGETS_OF_KSHV_MIR_K12_11            6             0.588   1.554   0.623
  SMIRNOV_RESPONSE_TO_IR_6HR_UP                  6             0.583   1.554   0.628
  PID_SHP2_PATHWAY                               3             0.738   1.542   0.629
  JIANG_VHL_TARGETS                              6             0.588   1.550   0.630
  SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12          18            0.408   1.555   0.631
  PLASARI_TGFB1_SIGNALING_VIA_NFIC_10HR_UP       5             0.628   1.543   0.632
  CHEN_PDGF_TARGETS                              4             0.668   1.545   0.632
  PID_IGF1_PATHWAY                               3             0.759   1.542   0.633
  NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN   32            0.349   1.555   0.633
  PID_BCR_5PATHWAY                               3             0.764   1.557   0.633

\*Number of genes on chromosome 3.

###### 

The top 10 gene sets/pathways from c2 curated gene sets ranked by FDR *q*values for DBP

  --------------------------------------------------------------------------------------------
  Pathway name                                        No. genes\*   ES      NES     FDR\
                                                                                    *q*value
  --------------------------------------------------- ------------- ------- ------- ----------
  PHONG_TNF_RESPONSE_VIA_P38_COMPLETE                 13            0.583   1.743   0.580

  DELYS_THYROID_CANCER_DN                             11            0.612   1.748   0.599

  CORRE_MULTIPLE_MYELOMA_DN                           3             0.897   1.733   0.603

  SHEPARD_BMYB_MORPHOLINO_UP                          10            0.609   1.712   0.617

  LI_INDUCED_T\_TO_NATURAL_KILLER_UP                  17            0.537   1.724   0.617

  WILCOX_PRESPONSE_TO_ROGESTERONE_UP                  6             0.705   1.700   0.621

  WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN                   13            0.562   1.674   0.632

  KEGG_RENIN_ANGIOTENSIN_SYSTEM                       3             0.932   1.761   0.632

  OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_DN   11            0.605   1.751   0.633

  REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION    16            0.535   1.685   0.644
  --------------------------------------------------------------------------------------------

\*Number of genes on chromosome 3

Because our pathway-based analysis is restricted to genes on chromosome 3, the number of pathways used for analysis exceeded the number of genes, which can have important implications in interpreting our findings. The results from our analyses should be interpreted cautiously.

Conclusions
===========

Gene-set enrichment analysis considers multiple genes that are related biologically. In our data, we identified 1 identical enriched gene set/pathway with the MAP and the difference between SBP and DBP. The gene CD47 in this pathway was reported previously to be related to BP.

Our analysis included only 129 unrelated individuals. Sample size plays a major role in identifying enriched gene sets/pathways, which could explain the lack of significant pathways in our analysis. Future studies can be done by applying GSEA on large family-based data where incorporating both rare and common variants, taking into account the correlations between individuals and increasing the sample size, may lead to new discoveries.

Competing interests
===================

The authors declare that they have no competing interests.

Authors\' contributions
=======================

HA designed the overall study; HA and XFL performed all of the data analysis. HA and JB drafted the manuscript and JB conceived the study and provided critical comments. All authors read and approved the final manuscript.

Acknowledgements
================

JB would like to acknowledge Discovery Grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) (grant number 293295-2009) and Canadian Institutes of Health Research (CIHR) (grant number 84392). JB holds the John D. Cameron Endowed Chair in the Genetic Determinants of Chronic Diseases, Department of Clinical Epide- miology and Biostatistics, McMaster University. The GAW18 whole genome sequence data were provided by the T2D-GENES Consortium, which is supported by NIH grants U01 DK085524, U01 DK085584, U01 DK085501, U01 DK085526, and U01 DK085545. The other genetic and phenotypic data for GAW18 were provided by the San Antonio Family Heart Study and San Antonio Family Diabetes/Gallbladder Study, which are supported by NIH grants P01 HL045222, R01 DK047482, and R01 DK053889. The Genetic Analysis Workshop is supported by NIH grant R01 GM031575. We would like to thank two anonymous reviewers and the editor for insightful comments that improved the presentation and clarity of our manuscript.

This article has been published as part of *BMC Proceedings*Volume 8 Supplement 1, 2014: Genetic Analysis Workshop 18. The full contents of the supplement are available online at <http://www.biomedcentral.com/bmcproc/supplements/8/S1>. Publication charges for this supplement were funded by the Texas Biomedical Research Institute.
